Human Anti-IL23A Recombinant Antibody (clone CNTO1959) (CAT#: PABL-241)

Recombinant Human Antibody (CNTO1959) is capable of binding to IL-23, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-IL-23 mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-IL-23 mAb and CL of human kappa light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 A, Expression of KRT16, IFN-γ, IL-17F, and LCN2 mRNA at baseline and week 12 in lesional and nonlesional biopsy specimens from patients treated with high-dose (100 mg + 300 mg) guselkumab compared with placebo. B, Microarray expression of 1224 transcripts of nonlesional skin at baseline versus lesional skin at baseline and at weeks 1 and 12 after guselkumab treatment.

Figure 1 A, Expression of KRT16, IFN-γ, IL-17F, and LCN2 mRNA at baseline and week 12 in lesional and nonlesional biopsy specimens from patients treated with high-dose (100 mg + 300 mg) guselkumab compared with placebo. B, Microarray expression of 1224 transcripts of nonlesional skin at baseline versus lesional skin at baseline and at weeks 1 and 12 after guselkumab treatment.

Sofen, H., Smith, S., Matheson, R. T., Leonardi, C. L., Calderon, C., Brodmerkel, C.,... & Wang, Y. (2014). Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. Journal of Allergy and Clinical Immunology, 133(4), 1032-1040.

Figure 2 Serum analyses of circulating IL-17A levels in guselkumab-treated responders (PASI 50 response at week 12) at baseline and at weeks 1 and 12 compared with the placebo-treated group. P values measure the significant difference in posttreatment compared with baseline values.

Figure 2 Serum analyses of circulating IL-17A levels in guselkumab-treated responders (PASI 50 response at week 12) at baseline and at weeks 1 and 12 compared with the placebo-treated group. P values measure the significant difference in posttreatment compared with baseline values.

Sofen, H., Smith, S., Matheson, R. T., Leonardi, C. L., Calderon, C., Brodmerkel, C.,... & Wang, Y. (2014). Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. Journal of Allergy and Clinical Immunology, 133(4), 1032-1040.

Figure 3 Evaluation of mean epidermal thickness and T-cell (CD3) and myeloid DC (CD11c) expression from lesional skin biopsy specimens at baseline and after guselkumab or placebo treatment at weeks 1 and 12.

Figure 3 Evaluation of mean epidermal thickness and T-cell (CD3) and myeloid DC (CD11c) expression from lesional skin biopsy specimens at baseline and after guselkumab or placebo treatment at weeks 1 and 12.

Sofen, H., Smith, S., Matheson, R. T., Leonardi, C. L., Calderon, C., Brodmerkel, C.,... & Wang, Y. (2014). Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. Journal of Allergy and Clinical Immunology, 133(4), 1032-1040.

Figure 4 Histologic evaluation of nonlesional and lesional skin at baseline and week 12 after subcutaneous injection of 300 mg of guselkumab. CD3, T cell; CD11c, myeloid DC; H&E, hematoxylin and eosin; KRT16, keratin 16.

Figure 4 Histologic evaluation of nonlesional and lesional skin at baseline and week 12 after subcutaneous injection of 300 mg of guselkumab. CD3, T cell; CD11c, myeloid DC; H&E, hematoxylin and eosin; KRT16, keratin 16.

Sofen, H., Smith, S., Matheson, R. T., Leonardi, C. L., Calderon, C., Brodmerkel, C.,... & Wang, Y. (2014). Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. Journal of Allergy and Clinical Immunology, 133(4), 1032-1040.


Specifications

  • Immunogen
  • Human interleukin 23, alpha subunit p19
  • Host Species
  • Human
  • Type
  • Human IgG
  • Specificity
  • Human IL23A
  • Species Reactivity
  • Human
  • Clone
  • CNTO1959
  • Applications
  • WB, ELISA, FuncS

Product Property

  • Purity
  • >95% as determined by SDS-PAGE and HPLC analysis
  • Concentration
  • Please refer to the vial label for the specific concentration.
  • Storage
  • Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Applications

  • Application Notes
  • The antibody was validated for Function Assay. For details, refer to Published Data.

Target

  • Alternative Names
  • IL23A; interleukin 23; alpha subunit p19; P19; SGRF; IL-23; IL-23A; IL23P19; interleukin-23 subunit alpha; IL-23-A; IL-23p19; IL-23 subunit alpha; interleukin 23 p19 subunit; interleukin-23 subunit p19; JKA3 induced upon T-cell activation; interleukin-six; G-CSF related factor

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone CNTO1959"

See other products for "IL23A"

Single-domain Antibody

CAT Product Name Application Type
NAB-1953-VHH Recombinant Anti-human IL23A VHH Single Domain Antibody WB, IP, ICC, FC, FA Llama VHH
TAB-005LC-VHH Anti-human IL23A Recombinant Antibody (119A3) (TAB-005LC-VHH) ELISA Single domain antibody

Chimeric Antibody

CAT Product Name Application Type
TAB-607LC Anti-human IL23A Recombinant Antibody (E11E7Chimera) (TAB-607LC) ELISA, Neut, FuncS Chimeric antibody (rat/human)
TAB-607LC-S(P) Anti-human IL23A scFv Fragment (E11E7Chimera) ELISA Chimeric antibody (rat/human)
TAB-607LC-F(E) Anti-human IL23A Fab Fragment (E11E7Chimera) ELISA Chimeric antibody (rat/human)

Humanized Antibody

CAT Product Name Application Type
TAB-616LC Anti-human IL23A Recombinant Antibody (A3M0) (TAB-616LC) ELISA, FC, Inhib, FuncS Humanized antibody
TAB-617LC Anti-human IL23A Recombinant Antibody (A3M1) (TAB-617LC) ELISA, FC, Inhib Humanized antibody
TAB-618LC Anti-human IL23A Recombinant Antibody (A3N1) (TAB-618LC) ELISA, FC, Inhib Humanized antibody
TAB-605LC-S(P) Anti-human IL23A scFv Fragment (FM303) ELISA Humanized antibody
TAB-608LC-S(P) Anti-human IL23A scFv Fragment (21-4) ELISA Humanized antibody

Rabbit Monoclonal Antibody

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-875 Afuco™ Anti-IL23A ADCC Recombinant Antibody (Tildrakizumab), ADCC Enhanced Neut, ELISA, IF, IP, FuncS, FC ADCC enhanced antibody
AFC-TAB-620LC Afuco™ Anti-IL23A ADCC Recombinant Antibody (Risankizumab), ADCC Enhanced ELISA ADCC enhanced antibody
AFC-TAB-008ML Afuco™ Anti-IL23A ADCC Recombinant Antibody (Brazikumab), ADCC Enhanced ELISA, IHC, FC, IP, IF, Inhib ADCC enhanced antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for PABL-241. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare